The protective effect of Thiamine (vitamin B1) for Bortezomib induced peripheral neuropathy in multiple myeloma
Phase 3
Recruiting
- Conditions
- neuropathy.
- Registration Number
- IRCT20190116042379N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
who were suspected to receive Bortezomib based chemotherapy regimen
Exclusion Criteria
do not have interfering factors such as: Previous history of symptomatic peripheral neuropathy, Diabetes mellitus, End stage renal disease, history of alcohol abuse, and any other neuromuscular disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method europathy. Timepoint: 4month. Method of measurement: experimental symptom-based questionnaire.
- Secondary Outcome Measures
Name Time Method